英硅智能：获美纳里尼3900万港币里程碑付款，合作项目MEN2501完成首例患者给药

Core Insights - The company Yingkui Intelligent announced the authorization of the MEN2501 project to Menarini Group, effective January 2025, following the completion of the first patient dosing in Phase I clinical trials [1] - Yingkui Intelligent has received a milestone payment of 39 million HKD from Menarini as part of their collaboration agreement [1] - MEN2501 is a highly differentiated small molecule inhibitor targeting the driver protein KIF18A, showing significant inhibitory activity against chromosomal instability cancers in preclinical data [1]